Annual mammography screening can save lives because breast cancer is a progressive disease and early detection enables improved prognosis due to appropriate treatment of small nonpalpable node-negative cancers. Multiple randomized controlled trials and observational studies have shown that mammography can reduce breast cancer mortality by 30% or more.

Digital breast tomosynthesis (DBT) first entered the breast imaging clinical arena when the Food and Drug Administration (FDA) approved DBT in 2011. Multiple studies have shown that DBT is effective in both mammography screening and diagnostic settings. Tomosynthesis has quickly emerged as a practice-changing standard that improves the clinical accuracy of a mammogram by increasing both sensitivity and specificity; thus, reducing the masking effect of overlapping fibroglandular tissue, thereby improving breast cancer detection. The improved accuracy and overall efficiency that DBT provides, will enhance radiologists’ performance and improve the patient experience.

Learning Objectives

• Discuss the importance of breast screening mammography.
• Incorporate the differences between, and benefits of 2D and 3D mammography into routine clinical practice.
• Apply 3D tomosynthesis to improve patient care, particularly in the management of patients with dense breasts.

No special educational preparation is required for this CME/CE Activity!

Supported through an unrestricted educational grant from FUJIFILM Medical Systems U.S.A., Inc.

In this second of a 3 Part Series, Dr. Laurie Fajardo discusses the benefits of digital breast tomosynthesis (DBT) for detecting and diagnosing breast cancer and things to consider when planning or implementing DBT into breast imaging practices.

Dr. Fajardo discusses the importance of radiation dose reduction with synthetic 2D, reviews the published literature on the performance of synthetic 2D mammography, and shares how DBT can impact data storage and network data transmission across your PACS and enterprise system.

Educational Objectives:
At the completion of this activity, participants should be able to:

• Describe the efficacy of synthetic 2D from DBT.
• Implement procedures for managing DBT data volumes and workflow.
• Develop an approach to interpreting DBT images.

Supported through an unrestricted educational grant from FUJIFILM Medical Systems U.S.A., Inc.

Digital breast tomosynthesis, also known as 3D DBT first entered the clinical arena in 2011 when the FDA approved its use. Multiple studies have since shown that tomosynthesis is effective in both the screening and the diagnostic setting. This technology has quickly emerged as a practice-changing standard by increasing both sensitivity and specificity, thereby improving breast cancer detection and the clinical accuracy of mammograms.

This Expert Forum educational program focuses on the impact of digital breast tomosynthesis and the role it plays in all aspects of breast screening. In this program, you will hear from an expert panel consisting of four (4) healthcare professionals from various specialties; who are all involved in the diagnosis, treatment and care of breast cancer patients and who will share their clinical insights and experience.

Educational Objectives:
At the completion of this activity, participants should be able to:

• Discuss the importance of breast screening mammography.
• Compare the differences between 2D and 3D mammography.
• Explain how the use of 3D DBT will benefit their patients.
• Increase the collaboration between radiologists and referring physicians.
• Implement best practices for concise communication across the continuum of care.

Supported through an unrestricted educational grant from FUJIFILM Medical Systems U.S.A., Inc.